Pidotimod dosing & administration

Name: Pidotimod Injection Dosage & Protocol
Creator: Michael Carroll

Synthetic dipeptide immunomodulator that enhances both innate and adaptive immunity through Toll-like receptor activation

Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards

400 – 800 mgSuggested dose

Multiple times dailyFrequency

OralRoute

12+ weeksCycle length

Dosing

How much do I take?

Oral: Taken by mouth as a capsule, tablet, or liquid.

Bioavailability Varies by compound — many peptides are largely broken down in the gut, so little reaches the blood intact; some small molecules absorb well.

2 documented dose levels — separate regimens, not a titration schedule

400 mg (pediatric, age >3 yr): twice daily for acute infection, once daily for prevention

Frequency

Twice daily (acute) or once daily (prevention)

Duration

15-20 days acute; up to 60 days for prevention

Approved pediatric dosing (Italy/Asia; not FDA-approved). Take 2 hours before or after food to preserve absorption. [2][6]

800 mg (adults): twice daily for acute infection, once daily for prevention

Frequency

Twice daily (acute) or once daily (prevention/maintenance)

Duration

8-15 days acute; up to ~60 days for prophylaxis

Standard adult dosing for acute respiratory infection with antibiotics, then once-daily maintenance. Take away from meals. [5][6]

Timing

Best time to take

Take Pidotimod at the same time each day for consistent blood levels. Morning dosing with breakfast is often preferred, but follow your healthcare provider's specific instructions.

With food?

Pidotimod can typically be taken with or without food. Taking it with a light meal may help reduce any GI discomfort. Avoid taking with grapefruit juice or high-fat meals unless specifically directed.

If stacking

Pidotimod should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.

Adjusting your dose

Increase if

You are an adult with documented immunodepression and using only once-daily dosing
You are experiencing an acute respiratory infection and need higher short-term dosing
Your healthcare provider recommends twice-daily dosing based on clinical assessment

Decrease if

You experience persistent gastrointestinal discomfort at the standard dose
You are transitioning from acute treatment to prevention (step down from twice to once daily)
You have mild kidney or liver impairment — consult your doctor about dose reduction

Signs of right dose

Fewer and less severe respiratory infections
Improved immune response to vaccination
Better overall immune function markers
Reduced frequency of illness episodes

PidotimodTwice daily (acute) or once daily (prevention)

How much peptide is in your bottle?

Look at the label on the vial. It’s the number next to mg — like "5 mg".

Type a number to continue.

Administration

How do I use it?

Reconstitution

What you need

Pidotimod in its prescribed formClean, dry storage containerMeasuring device if applicable (oral syringe, measuring cup)Calendar or reminder app for dosing schedule

Injection

Route

Pidotimod is administered Oral (tablet)—no injection required

Best sites

Not applicable—this is not an injectable formulation

Storage

Before reconstitution

Store Pidotimod in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.

After reconstitution

Once reconstituted, Pidotimod should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.

Signs of degradation — discard the vial

Solution appears cloudy, discolored, or contains visible particles (should be clear)Product has been exposed to temperatures outside the recommended storage rangeProduct has been frozen (unless specifically designed for freeze-thaw stability)Expiration date has passed or reconstituted solution has exceeded its use-by dateUnusual odor, color change, or visible contamination

Sample daily schedule

As prescribed (twice daily)

As prescribed by your healthcare provider injection

Site: Oral (tablet)—rotate sites if applicable

Maintain a consistent schedule for optimal results with Pidotimod. Set reminders if needed. If you miss a dose, follow your healthcare provider's instructions—do not double up on doses to compensate.

Safety

Is it safe?

Side effects

Commonly reported: Gastrointestinal discomfort, Skin rash, Headache, Nausea, Diarrhea, Transient fever

Less common: Allergic reaction

Stop and seek help if

Severe or worsening side effects that don't improve with dose adjustment or supportive care
Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
Your healthcare provider recommends discontinuation based on your clinical response
Development of any new medical condition that may be contraindicated with Pidotimod
Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
Abnormal lab results or clinical markers that suggest adverse effects

Pidotimod should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.

Flagged pairings

Immunosuppressants (cyclosporine, tacrolimus) — Pidotimod's immune-stimulating effects may counteract the immunosuppressive action of these drugs. Avoid concurrent use or use only under close medical supervision.

Full safety profile

Published research